A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes
Status:
Completed
Trial end date:
1994-10-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose (MTD) of hypericin, to define the types of toxicities
that may be observed, and to determine what doses of the drug are associated with
improvements in virological and immunological surrogate markers of HIV infection. To
determine the bioavailability of synthetic hypericin given in 2 percent benzyl alcohol
solution.
Hypericin is unlike other drugs presently being used to treat AIDS patients. Hypericin shows
anti-HIV activity in test tube experiments.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)